NHI-2 is a novel, potent, selective and cell membrane permeable inhibitor of human lactate dehydrogenase isoform A (LDH-A; IC50 values 14.7 μM and 55.8 μM in a NADH competition assay for LDH-A and LDH-B, respectively), whcih is a key enzyme necessary to sustain glycolysis, the major pathway used by many cancer cells for cell growth and proliferation (the Warburg effect). It acts by reducing lactate production in HeLa cells and has anti-glycolytic activity against a variety of cancer cells. NHI-2 inhibited cell growth of pancreatic cancer LPC006 and PANC-1 cells and enhanced the antiproliferative effects of Gemcitabine and caused apoptosis in colon cancer HCT116 cells.

纯度：≥98%

CAS：1269802-97-2